TheraRadar
← Back
Data updated: Mar 29, 2026

VANGARD

CardiovascularNeurologyOphthalmology
Generics

VANGARD is a generic drug manufacturer focused on Cardiovascular, Neurology, Ophthalmology.

1981
Since
26
Drugs
-
Trials
138
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

CHLORPROMAZINE HYDROCHLORIDE 2026-01-26
ACETAZOLAMIDE 2026-01-12
Labeling
AMITRIPTYLINE HYDROCHLORIDE 2026-01-09
Labeling
ACETAZOLAMIDE 2026-01-08
Labeling
ACETAZOLAMIDE 2026-01-08
Labeling
ACETAZOLAMIDE 2026-01-08
Labeling
MECLIZINE HYDROCHLORIDE 2026-01-06
Labeling
ACETAZOLAMIDE 2025-11-25
Manufacturing (CMC)
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 29%
2 drugs
Neurology 29%
2 drugs
Ophthalmology 14%
1 drugs
Dermatology 14%
1 drugs
Gastroenterology 14%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

BAUSCH specialty
Dermatology, Ophthalmology, Cardiovascular, Gastroenterology
Baxter specialty
Cardiovascular, Dermatology, Ophthalmology
Bayer big-pharma
Cardiovascular, Ophthalmology, Dermatology
B BRAUN specialty
Ophthalmology, Dermatology, Cardiovascular
BAUSCH AND LOMB specialty
Ophthalmology, Cardiovascular, Dermatology